Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Subklewe

Showing results (221-230 of 244) with videos related to

Pageof 25
Sort By:
Blood Advances|October 22, 2025
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell EngagersGiulia Magno, Kai Rejeski, Giulia Rappa, et al.
Blood Cancer Journal|August 26, 2025
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphomaMichael Winkelmann, Sandeep S Raj, Michael D Jain, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Blood|July 19, 2021
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibodyChristian Augsberger, Gerulf Hänel, Wei Xu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effectsCarolin Ertl, Theresa Ruf, Dirk Mentzer, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Blood Cancer Discovery|January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell LymphomaRawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Hemasphere|July 8, 2021
COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell LymphomaErik Gaitzsch, Verena Passerini, Elham Khatamzas, et al.
Blood|June 10, 2023
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendationsKai Rejeski, Marion Subklewe, Mahmoud Aljurf, et al.
Blood Advances|August 19, 2025
International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AMLSwati Naik, Richard Aplenc, Susanne H C Baumeister, et al.
Pageof 25

Showing results (221-230 of 244) with videos related to

Sort By:
Pageof 25
Blood Advances|October 22, 2025
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell EngagersGiulia Magno, Kai Rejeski, Giulia Rappa, et al.
Blood Cancer Journal|August 26, 2025
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphomaMichael Winkelmann, Sandeep S Raj, Michael D Jain, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Blood|July 19, 2021
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibodyChristian Augsberger, Gerulf Hänel, Wei Xu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effectsCarolin Ertl, Theresa Ruf, Dirk Mentzer, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Blood Cancer Discovery|January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell LymphomaRawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Hemasphere|July 8, 2021
COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell LymphomaErik Gaitzsch, Verena Passerini, Elham Khatamzas, et al.
Blood|June 10, 2023
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendationsKai Rejeski, Marion Subklewe, Mahmoud Aljurf, et al.
Blood Advances|August 19, 2025
International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AMLSwati Naik, Richard Aplenc, Susanne H C Baumeister, et al.
Pageof 25